Raffaele Colombo
Raffaele Colombo/LinkedIn

Raffaele Colombo: Late-Breaking Abstracts Related to ADCs at ESMO25

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:

“Late-breaking abstracts related to ADCs at ESMO25 (LBA16 and LBA21 have not yet been released).

More than 10% of LBAs are on ADCs!”

Raffaele Colombo

More posts featuring ESMO2025 on OncoDaily.